Myocardial DysfunctionNCT04060381
Myocardial Deformation Before and After Birth
An observational study of Myocardial Dysfunction and Newborn Morbidity, run by Haukeland University Hospital at 1 site in Norway.
Trial summary
Knowledge on the changes in myocardial function in the last weeks before birth and during the first year of life is limited. Through fetal and post-natal echocardiography we intend to describe these changes using myocardial tissue recognition techniques (Speckle tracking echocardiography and Tissue Doppler… Read more about this study
- Who is it for?
- Ages Up to 3 weeks
- Conditions the study is for
- Myocardial Dysfunction, Newborn Morbidity, Maternal Obesity
- What is being tested?
- Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine
- How many people
- 300 participants
- Where
- 1 siteNorway
- Study dates
- 4 Apr 2017to Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 3 weeks
- All sexes
- No healthy volunteers
- Child
Study population: Either recruited during pregnancies or as newborns
Who may be able to join
- Normal pregnancies
- Newborns in need of blood transfusion
- Newborns in need of medical closure of the arterial duct
- Maternal obesity
Who cannot join
- Abnormal pregnancies except maternal obesity
- Congenital heart defects
- Other malformation syndromes
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Myocardial Deformation Before and After Birth, and Under Altered Preload, Afterload and Heart Rate in New-borns
Knowledge on the changes in myocardial function in the last weeks before birth and during the first year of life is limited. Through fetal and post-natal echocardiography we intend to describe these changes using myocardial tissue recognition techniques (Speckle tracking echocardiography and Tissue Doppler echocardiography) in healthy neonates, born to term of healthy women after uncomplicated pregnancies. We will compare the findings in this cohort to a cohort of neonates born to term of women with severe pre-pregnancy obesity.
Sick neonates in intensive care units with various cardiac and non-cardiac conditions are often exposed to treatment that may affect both their cardiac function and important echo-variables per se. Using echocardiography, we will examine these changes in neonates treated with blood transfusion, catecholamines and in those treated with Ibuprofen due to a haemodynamic significant arterial duct.
Read the detailed description
Before, during and after birth major changes take place in the cardiovascular system. The last weeks prior to birth there is an oxidative stress and after birth, there is normally a large step up in blood oxygen tension when the lungs take over oxidation of the blood. Simultaneously there are changes in the vascular resistance in both the pulmonary- and systemic part of the circulation and ductus venous, the arterial duct, and foramen ovale close. Combined these will significantly alter the physical conditions under which the myocardium is supposed to work.
This project will have five arms, all based on measurements of myocardial function and coronary perfusion by speckle tracking echocardiography (STE) in the last trimester of the pregnancy and in newborns with different gestational age and in sick newborns where myocardial function is affected by medical treatment or is an important part of the clinical situation.
- Obtaining normal values for strain during the last trimester of the pregnancy and the first days after birth in child born to term. Hypothesis: After birth, there will be higher STE values in the left ventricle than before birth. This will increase further the first days post-partum in parallel with an altered hemodynamic situation and oxygen demand of the infant. The STE changes will take place at the same time, as there is an increased Doppler velocity in the aorta, the pulmonary artery and the coronary arteries Mothers (N= 150) will be recruited when they are coming to a routine fetal ultrasound scan. It will be made an echo-examination once per week from week 37 until birth. After birth the degree of placental transfusion (late cord clamping or not) will be noticed. Ventricular size, Doppler velocities in the ascending aorta and pulmonary artery, STE and coronary flow during the first three days of life and one year of age will be assessed
- Evaluate the effect of maternal obesity on cardiac function in newborns up to one year of age. Hypothesis: Maternal sever obesity will result in reduced cardiac function in their neonates. However, cardiac function will normalize within the first year of life. A reduction in afterload will reduce strain measured by STE and coronary. Mothers (N=75) with sever obesity will be recruited from the outpatient clinic for obese women. First day after birth, the newborn will have a comprehensive echocardiographic examination within the first few hours, then the two following days, at the day equivalent to gestational age 42+0 weeks and finally at 1 year of age. Cardiac morphology, ventricular sizes and Doppler velocities in the ascending aorta and pulmonary artery as well as a strain measured by STE for both ventricles will be assessed. Fetal malformations or diseases will result in exclusion from the study.
- Measuring deformation when preload is increased by intravenous fluid treatment and blood transfusion Hypothesis: Increased preload in the form of saline infusion or blood transfusion will result in a temporary increase of STE and coronary blood flow. Newborns (N=25 blood transfusion and 25 NaCl-infusion) who need infusion of sodium chloride (NaCl 9mg) / ml or transfusion of packed red blood cellssuspended in 100 mL of saline- adenine-glucose-mannitol (SAGMAN) will be recruited. To obtain rehydration or optimization of intravascular volume it is common to provide NaCl 9 mg/ml, 10-20 ml/kg in 10-120 minutes. Blood transfusion is used in severe anemia and hemolytic diseases. The regular blood transfusion dose is SAGMAN packed red blood cells10-15ml/ kg body weight over 2-3 hours. Children requiring exchange transfusion, with heart failure or congenital heart defects will be excluded.
- Measuring deformation when afterload and heart rate are increased during infusion of catecholamines. Hypothesis: Dopamine, epinephrine and/ or nor-epinephrine will increase heart rate and blood pressure and due to this increase the strain measured by STE, coronary blood flow, and Doppler velocity in the aorta pulmonary artery. Newborns (N=25) who need dopamine (2.5 to 15 ug/kg /min iv.) and or epinephrine / nor-epinephrine to maintain an adequate blood pressure will be recruited. Only children where an echo-exam before starting treatment is possible will be recruited. If the treatment does not achieve a rise in the blood pressure above the 2.5 percentile for gestational age, the baby will be excluded.
- Measuring deformation when afterload (volume) is reduced following pharmacological closure of a patent ductus arteriosus.
Hypothesis: A reduction in afterload will reduce strain measured by STE and coronary.
Patients (N=25) with a suspected patent ductus arteriosus (PDA) are always referred to echocardiography before starting treatment with Indomethacin and after the treatment has stopped. Present clinical procedures for closure of the ductus will be followed, . Time of echocardiography will be standardized to just before and at least 12 hours after the last dose of Ibuprofen has been provided (t½ ≈ 2.5-11 hrs.).
- Conditions
- Myocardial Dysfunction, Newborn Morbidity, Maternal Obesity
- Being tested
- Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine
- Keywords
- Spackle tracking echocardiography, Tissue doppler, Neonates, Infants, Maternal obesity
- Medical subject headings
- Pregnancy in Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamineDrug
Also called Volume treatment, Blood pressure elevation
Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
| Study group | Role | What they receive |
|---|---|---|
| Fetuses of normal weight women | Fetuses of normal pregnancies of normal weight mothers are included from gestational week 37 | |
| Fetuses of severely obese women | Fetuses of normal pregnancies of severly obese mothers are included from gestational week 37 | |
| New-borns in need of blood transfusion | Neonates mainly receive blood due to blood loss, often because of repeated blood sampling Receives: Drug: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine | |
| New-borns in need for closure of the arterial duct | Neonates mainly receive medication (Ibuprofen) because of symptoms like apnea, due to their patent arterial duct. Receives: Drug: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in myocardial function
Per cent change in longitudinal global strain
Measured: Maximum 1 year and 5 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2019
- Study start4 Apr 2017
- Primary completionDec 2023 (estimated)
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Haukeland University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gottfried Greve, Haukeland University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04060381
- Sponsor's protocol ID
- 2015/1918
- Status last verified
- Mar 2023
- First submitted
- 15 Aug 2019
- Last updated
- 6 Mar 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Eventually strain data.
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Myocardial Deformation Before and After Birth, and Under Altered Preload, Afterload and Heart Rate in New-borns
- ClinicalTrials.gov ID
- NCT04060381
- Acronym / sponsor ID
- 2015/1918
- Conditions
- Myocardial Dysfunction, Newborn Morbidity, Maternal Obesity
- Keywords
- Spackle tracking echocardiography, Tissue doppler, Neonates, Infants, Maternal obesity
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Haukeland University HospitalUniversity, hospital or other
- Study start
- 4 Apr 2017 (actual)
- Primary completion
- Dec 2023 (estimated)
- Study completion
- Dec 2025 (estimated)
- First posted
- 19 Aug 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Knowledge on the changes in myocardial function in the last weeks before birth and during the first year of life is limited. Through fetal and post-natal echocardiography we intend to describe these changes using myocardial tissue recognition techniques (Speckle tracking echocardiography and Tissue Doppler echocardiography) in healthy neonates, born to term of healthy women after uncomplicated pregnancies. We will compare the findings in this cohort to a cohort of neonates born to term of women with severe pre-pregnancy obesity.
Sick neonates in intensive care units with various cardiac and non-cardiac conditions are often exposed to treatment that may affect both their cardiac function and important echo-variables per se. Using echocardiography, we will examine these changes in neonates treated with blood transfusion, catecholamines and in those treated with Ibuprofen due to a haemodynamic significant arterial duct.
Detailed description
Before, during and after birth major changes take place in the cardiovascular system. The last weeks prior to birth there is an oxidative stress and after birth, there is normally a large step up in blood oxygen tension when the lungs take over oxidation of the blood. Simultaneously there are changes in the vascular resistance in both the pulmonary- and systemic part of the circulation and ductus venous, the arterial duct, and foramen ovale close. Combined these will significantly alter the physical conditions under which the myocardium is supposed to work.
This project will have five arms, all based on measurements of myocardial function and coronary perfusion by speckle tracking echocardiography (STE) in the last trimester of the pregnancy and in newborns with different gestational age and in sick newborns where myocardial function is affected by medical treatment or is an important part of the clinical situation.
- Obtaining normal values for strain during the last trimester of the pregnancy and the first days after birth in child born to term. Hypothesis: After birth, there will be higher STE values in the left ventricle than before birth. This will increase further the first days post-partum in parallel with an altered hemodynamic situation and oxygen demand of the infant. The STE changes will take place at the same time, as there is an increased Doppler velocity in the aorta, the pulmonary artery and the coronary arteries Mothers (N= 150) will be recruited when they are coming to a routine fetal ultrasound scan. It will be made an echo-examination once per week from week 37 until birth. After birth the degree of placental transfusion (late cord clamping or not) will be noticed. Ventricular size, Doppler velocities in the ascending aorta and pulmonary artery, STE and coronary flow during the first three days of life and one year of age will be assessed
- Evaluate the effect of maternal obesity on cardiac function in newborns up to one year of age. Hypothesis: Maternal sever obesity will result in reduced cardiac function in their neonates. However, cardiac function will normalize within the first year of life. A reduction in afterload will reduce strain measured by STE and coronary. Mothers (N=75) with sever obesity will be recruited from the outpatient clinic for obese women. First day after birth, the newborn will have a comprehensive echocardiographic examination within the first few hours, then the two following days, at the day equivalent to gestational age 42+0 weeks and finally at 1 year of age. Cardiac morphology, ventricular sizes and Doppler velocities in the ascending aorta and pulmonary artery as well as a strain measured by STE for both ventricles will be assessed. Fetal malformations or diseases will result in exclusion from the study.
- Measuring deformation when preload is increased by intravenous fluid treatment and blood transfusion Hypothesis: Increased preload in the form of saline infusion or blood transfusion will result in a temporary increase of STE and coronary blood flow. Newborns (N=25 blood transfusion and 25 NaCl-infusion) who need infusion of sodium chloride (NaCl 9mg) / ml or transfusion of packed red blood cellssuspended in 100 mL of saline- adenine-glucose-mannitol (SAGMAN) will be recruited. To obtain rehydration or optimization of intravascular volume it is common to provide NaCl 9 mg/ml, 10-20 ml/kg in 10-120 minutes. Blood transfusion is used in severe anemia and hemolytic diseases. The regular blood transfusion dose is SAGMAN packed red blood cells10-15ml/ kg body weight over 2-3 hours. Children requiring exchange transfusion, with heart failure or congenital heart defects will be excluded.
- Measuring deformation when afterload and heart rate are increased during infusion of catecholamines. Hypothesis: Dopamine, epinephrine and/ or nor-epinephrine will increase heart rate and blood pressure and due to this increase the strain measured by STE, coronary blood flow, and Doppler velocity in the aorta pulmonary artery. Newborns (N=25) who need dopamine (2.5 to 15 ug/kg /min iv.) and or epinephrine / nor-epinephrine to maintain an adequate blood pressure will be recruited. Only children where an echo-exam before starting treatment is possible will be recruited. If the treatment does not achieve a rise in the blood pressure above the 2.5 percentile for gestational age, the baby will be excluded.
- Measuring deformation when afterload (volume) is reduced following pharmacological closure of a patent ductus arteriosus.
Hypothesis: A reduction in afterload will reduce strain measured by STE and coronary.
Patients (N=25) with a suspected patent ductus arteriosus (PDA) are always referred to echocardiography before starting treatment with Indomethacin and after the treatment has stopped. Present clinical procedures for closure of the ductus will be followed, . Time of echocardiography will be standardized to just before and at least 12 hours after the last dose of Ibuprofen has been provided (t½ ≈ 2.5-11 hrs.).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Fetuses of normal weight women | – | –Fetuses of normal pregnancies of normal weight mothers are included from gestational week 37 |
| Fetuses of severely obese women | – | –Fetuses of normal pregnancies of severly obese mothers are included from gestational week 37 |
| New-borns in need of blood transfusion | – | Drug: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamineNeonates mainly receive blood due to blood loss, often because of repeated blood sampling |
| New-borns in need for closure of the arterial duct | – | Drug: Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamineNeonates mainly receive medication (Ibuprofen) because of symptoms like apnea, due to their patent arterial duct. |
Who may qualify
- Ages
- Up to 3 weeks
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Either recruited during pregnancies or as newborns
Key inclusion criteria (4 listed)
- Normal pregnancies
- Newborns in need of blood transfusion
- Newborns in need of medical closure of the arterial duct
- Maternal obesity
Key exclusion criteria (3 listed)
- Abnormal pregnancies except maternal obesity
- Congenital heart defects
- Other malformation syndromes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamineAlso: Volume treatment, Blood pressure elevationTreatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit | Drug | New-borns in need for closure of the arterial duct, New-borns in need of blood transfusion |
Primary outcome
Changes in myocardial function
Time frame: Maximum 1 year and 5 weeks
Per cent change in longitudinal global strain
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2023.
- Individual participant dataSharing planned: Undecided. Eventually strain data.
Related trials for Myocardial Dysfunction
Not yet recruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Recruiting
Mental Stress Reactivity in Women With CMD
Post-menopause
Active, not recruiting
Insulin Resistance and Coronary Microvascular Dysfunction in Patients With Myocardial Ischemia and Non-obstructive Coronary Artery Disease
Coronary Microvascular Dysfunction, Coronary Microvascular Disease
Active, not recruitingObservational study
The DISCOVER INOCA Prospective Multi-center Registry
Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction
Not yet recruitingPhase 2
Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis
Transthyretin Cardiac Amyloidosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Dysfunction and Newborn Morbidity, run by Haukeland University Hospital at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 6 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in myocardial function (time frame: Maximum 1 year and 5 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2023.